TrumpRx launches with Zepbound listed at $299 and Mounjaro at $499

The federal drug price site TrumpRx.gov went live on February 5, 2026, listing the tirzepatide brands Zepbound and Mounjaro with cash prices and routing buyers to Eli Lilly's LillyDirect for both orders ^[1][2][3][4].

On the Zepbound vial page, TrumpRx shows an original price of $1,087.00, a listed savings of $788.00 and a final price of $299.00 ^[1]. The site's home page also lists Zepbound at $299 a month against $1,087 ^[4]. The Mounjaro page shows an original price of $1,112.16, listed savings of $613.16 and a final price of $499.00 ^[2].

Both pages present the figures as out-of-pocket prices, and each tells visitors that if they have insurance they should check their co-pay first because it may be even lower ^[1][2]. Both listings say eligibility is required and that terms and conditions apply, with links to Lilly's own terms ^[1][2]. Zepbound is listed in a vial at strengths of 2.5, 5, 7.5, 10, 12.5 and 15 mg ^[1]. Mounjaro is listed as a single-dose pen at strengths from 2.5/0.5 to 15/0.5 mg/mL ^[2]. LillyDirect handles eligibility confirmation and delivery options, with customer care available by phone Monday through Friday, 9 a.m. to 7 p.m. ET ^[1][2]. The home page says more than $700,000,000 has been saved for Americans ^[4].

The posted numbers do not match everywhere. A Pharmacy Times commentary published March 26, 2026 describes tirzepatide injections on TrumpRx at $299 to $449, compared with $1,087 ^[3], while the Mounjaro product page lists $499.00 ^[2]. The same commentary lists semaglutide tablets at $149 to $299 compared with $1,349, and semaglutide injections at $199 to $349 compared with $1,349 ^[3]. The TrumpRx home page shows the Wegovy pill at $149 a month against $1,349, the Wegovy pen at $199 against $1,349, and Ozempic at $199 against $1,028 ^[4]. TrumpRx did not publish an explanation of the differences.

The launch came as federal and manufacturer pressure on compounded GLP-1 products increased. TrumpRx went live on February 5, 2026, the same day Hims & Hers advertised the commercial launch of a compounded semaglutide tablet ^[3]. On February 6, 2026, the FDA said it would take steps to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded products and warned that violations could lead to legal action without further notice, including seizure and injunction; the agency named Hims & Hers ^[3]. On February 9, 2026, Novo Nordisk sued Hims & Hers for patent infringement over compounded semaglutide ^[3]. The FDA had issued more than 55 warning letters to online sellers of compounded GLP-1 products on September 16, 2025 ^[3].

Why it matters for patients

The TrumpRx figures are cash prices for FDA-approved tirzepatide, not a statement of what an insured patient pays. The site itself says to check a co-pay first, since insurance may be lower ^[1][2]. Eligibility rules and the full terms are set by Lilly and are not summarized next to the prices ^[1][2]. Zepbound and Mounjaro are both tirzepatide, but the two listings cover different product forms, a vial and a single-dose pen, and the posted prices differ ^[1][2]. For semaglutide, the listings shown on the home page run from $149 to $199 a month depending on the product ^[4]. Whether a particular patient qualifies for these prices, and what a retail pharmacy would charge instead, has not been disclosed.

What happens next

The FDA's February 6, 2026 statement said violations could lead to legal action without further notice ^[3]. Novo Nordisk's patent suit against Hims & Hers was filed February 9, 2026, and no outcome has been reported ^[3]. An FDA warning letter to 503A pharmacy Boothwyn Pharmacy was issued January 16, 2026, and published February 10, 2026, citing insanitary conditions and strength, quality or purity issues with compounded products ^[3]. TrumpRx's own FAQ asks whether the site will add more retail and mail-order pharmacy options over time; no answer or timeline is given ^[4].